Eiger BioPharmaceuticals, Inc. - Product Pipeline Review - 2012


#138228

25pages

Global Markets Direct

$ 1500

In Stock


Eiger BioPharmaceuticals, Inc. Product Pipeline Review 2012

Global Market Directs pharmaceuticals report, Eiger BioPharmaceuticals, Inc. Product Pipeline Review 2012 provides data on the Eiger BioPharmaceuticals, Inc.s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, Eiger BioPharmaceuticals, Inc.s corporate website, SEC filings, investor presentations and featured press releases, both from Eiger BioPharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Directs team.

Scope

  • Eiger BioPharmaceuticals, Inc. Brief Eiger BioPharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Eiger BioPharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Eiger BioPharmaceuticals, Inc. with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
  • Recent updates of the Eiger BioPharmaceuticals, Inc.s pipeline in the last quarter. 
  • Key discontinued and dormant projects. 
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate Eiger BioPharmaceuticals, Inc.s strategic position with total access to detailed information on its product pipeline. 
  • Assess the growth potential of Eiger BioPharmaceuticals, Inc. in its therapy areas of focus. 
  • Identify new drug targets and therapeutic classes in the Eiger BioPharmaceuticals, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
  • Exploit collaboration and partnership opportunities with Eiger BioPharmaceuticals, Inc.. 
  • Avoid Intellectual Property Rights related issues. 
  • Explore the dormant and discontinued projects of Eiger BioPharmaceuticals, Inc. and identify potential opportunities in those areas.
Table of Contents

Table of Contents 2

List of Tables 3
List of Figures 3
Eiger BioPharmaceuticals, Inc. Snapshot 4
Eiger BioPharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Eiger BioPharmaceuticals, Inc. Research and Development Overview 5
Key Therapeutic Areas 5
Eiger BioPharmaceuticals, Inc. Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products Monotherapy 8
Eiger BioPharmaceuticals, Inc. Pipeline Products Glance 9
Eiger BioPharmaceuticals, Inc. Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Eiger BioPharmaceuticals, Inc. Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Eiger BioPharmaceuticals, Inc. Drug Profiles 11
clemizole 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
EBP-1597 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
EBP-921 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
EBP-994 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Eiger BioPharmaceuticals, Inc. Pipeline Products by Route of Administration 15
Eiger BioPharmaceuticals, Inc. Pipeline Products By Mechanism of Action 16
Eiger BioPharmaceuticals, Inc. Recent Pipeline Updates 17
Eiger BioPharmaceuticals, Inc. Locations And Subsidiaries 18
Head Office 18
Financial Deals Landscape 19
Eiger BioPharmaceuticals, Inc., Deals Summary 19
Eiger BioPharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 20
Venture Financing 20
Eiger Biopharma Raises $1 Million In Third Tranche Of Series A Financing 20
Eiger BioPharma Secures An Additional $3.55 Million In Series A Financing 21
Eiger BioPharma Secures $7.1 Million In Series A Financing 22
Licensing Agreements 23
Stanford University Enters Into Worldwide Licensing Agreement With Eiger BioPharma 23

Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25

Eiger BioPharmaceuticals, Inc., Key Information 4
Eiger BioPharmaceuticals, Inc., Key Facts 4
Eiger BioPharmaceuticals, Inc. Pipeline by Indication, 2012 6
Eiger BioPharmaceuticals, Inc. Pipeline by Stage of Development, 2012 7
Eiger BioPharmaceuticals, Inc. Monotherapy Products in Pipeline, 2012 8
Eiger BioPharmaceuticals, Inc. Phase I, 2012 9
Eiger BioPharmaceuticals, Inc. Pre-Clinical, 2012 10
Eiger BioPharmaceuticals, Inc. Pipeline By Route of Administration, 2012 15
Eiger BioPharmaceuticals, Inc. Pipeline Products By Mechanism of Action, 2012 16
Eiger BioPharmaceuticals, Inc. Recent Pipeline Updates, 2012 17
Eiger BioPharmaceuticals, Inc., Deals Summary 19
Eiger Biopharma Raises $1 Million In Third Tranche Of Series A Financing 20
Eiger BioPharma Secures An Additional $3.55 Million In Series A Financing 21
Eiger BioPharma Secures $7.1 Million In Series A Financing 22
Stanford University Enters Into Worldwide Licensing Agreement With Eiger BioPharma 23
Eiger BioPharmaceuticals, Inc. Pipeline by Indication, 2012 6
Eiger BioPharmaceuticals, Inc. Pipeline by Stage of Development, 2012 7
Eiger BioPharmaceuticals, Inc. Monotherapy Products in Pipeline, 2012 8
Eiger BioPharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012 16